Epilepsy is a neurodegenerative disease closely associated with mitochondrial oxidative stress and neuronal damage, posing a grave threat to human health. Hypochlorous acid (HClO), a potent oxidant, has been demonstrated to play a critical role in the occurrence and progression of epilepsy. Accordingly, the development of a mitochondrial-targeted responsive HClO fluorescent probe could serve as a powerful tool for the early diagnosis of epilepsy and high-throughput screening (HTS) of natural neuroprotective. Herein, we report a mitochondria-targeted fluorescent probe (MB-Mito) with excellent selectivity, rapid activation kinetics, and blood-brain barrier (BBB) permeability, which is used for real-time and in situ tracking of HClO fluctuations in epilepsy models. More significantly, a visual HTS platform for natural neuroprotective agents was established based on MB-Mito, and an effective neuroprotective agent, myricetin, was identified from 47 natural compounds with potential antioxidant activity. Mechanistic studies have demonstrated that myricetin activates the ERK/Nrf2/HO-1 signaling pathway to mitigate mitochondrial oxidative stress, thereby providing precise treatment for epilepsy. All studies have confirmed that MB-Mito is a reliable tool for precise monitoring of HClO, drug HTS and mechanism research, promoting advances in the diagnosis and treatment of epilepsy.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: